FDA Clinical Trials FDA Regulations Regulatory Agencies Mifepristone NHS Generic Drugs Regulatory Affairs EU Regulations GLP-1 Drugs NHS Policies FDA Approval Alzheimer's Disease NHS Treatments Esketamine Unapproved Drugs Antipsychotic Medications Insurance Coverage FDA Designation Antibiotics Biotechnology Weight Management Infant Medicine Radioligand Therapy Cardiovascular Health Bristol Myers Squibb TGA Opioid Alternatives Regulatory Processes Regulatory Authorities Blood Disorder Treatment Xolair European Medicines Agency Mounjaro Regulations Oncology Vorasidenib Nasal Spray FDA Drug Approval MHRA Aifa Eli Lilly EU Commission Public Health Guidelines FDA Processes Therapeutic Goods Administration China Sanofi Generic Medications Non-Hormonal Treatments Imdelltra
The court said routine FDA-compliant labels and ordinary marketing do not by themselves prove inducement and set a higher bar requiring clear affirmative steps to encourage patented uses.
